Board Requires Settlement Agreement to Dismiss Pre-Institution Proceeding, PTAB Litigation Blog
Visit the PTAB Litigation Blog.
Biofrontera AG (“Petitioner”) filed an unopposed motion to dismiss the petition during the preliminary phase of the proceedings. Here, DUSA Pharmaceuticals, Inc. (“Patent Owner”) had not yet filed a Preliminary Response, and the Board has not issued a decision on whether to institute trial. But because Petitioner did not file the parties’ recent settlement agreement (which resolved, among other things, the parties’ instant dispute regarding the challenged patent) with its motion, the Board dismissed the motion without prejudice to refile with the settlement agreement.
Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
